Managing vision problems

Pless, Misha
June 2006
Inside MS;Jun/Jul2006, Vol. 24 Issue 3, p53
Academic Journal
The article provides information on the management of vision problems associated with multiple sclerosis (MS). If MS is the culprit, the single most important thing a person can do is to begin treatment with a disease-modifying drug. Some relief from optic neuritis pain may be provided by cold compresses applied to the eye. Should MS damage vision permanently despite good care, there are a number of aids to help people adapt.


Related Articles

  • MS Medicine Reduces Vision Loss in Patients.  // Review of Optometry;5/15/2007, Vol. 144 Issue 5, p10 

    The article presents a study which identifies the capability of natalizumab, a medicine for manage relapse rates in patients with multiple sclerosis, to reduce the chances of vision loss. The said study was conducted by the University of Pennsylvania. It is noted that vision loss is due to...

  • Current Management of Pain Associated with Multiple Sclerosis. Pöllmann, Walter; Feneberg, Wolfgang // CNS Drugs;2008, Vol. 22 Issue 4, p291 

    While pain is a common problem in patients with multiple sclerosis (MS), it is not frequently mentioned by patients and a more direct approach is required in order to obtain information about pain from patients. Many patients with MS experience more than one pain syndrome; combinations of...

  • Effects of Topiramate on Dysaesthetic Pain in a Patient with Multiple Sclerosis. Siniscalchi, Antonio; Gallelli, Luca; De Sarro, Giovambattista // Clinical Drug Investigation;2013, Vol. 33 Issue 2, p151 

    Dysaesthetic pain is a common neuropathic pain in patients with multiple sclerosis. Both tricyclic antidepressants (i.e., amitriptyline and duloxetine) and antiepileptic drugs (i.e., carbamazepine, gabapentin and pregabalin) represent first-line treatment of neuropathic pain. However,...

  • Pain in multiple sclerosis: A biopsychosocial perspective. Kerns, Robert D.; Kassirer, Marilyn; Otis, John // Journal of Rehabilitation Research & Development;Mar/Apr2002, Vol. 39 Issue 2, p225 

    Recommends a multidimensional approach to assessment and management of multiple sclerosis (MS). Details on the prevalence and management of multiple sclerosis-related pain; Psychosocial impact of pain in MS; Information on a biopsychosocial model of chronic pain in MS; Conclusions.

  • More ways to read. Figueroa, Martha // Momentum (19403410);Winter2012/2013, Vol. 6 Issue 1, p8 

    A letter to the editor is presented in response to the article "11 online resources for the visually impared," by Stephanie Watson in the Fall 2012.

  • Genzyme reports encouraging data from Phase II multiple sclerosis trial.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p18 

    The article reports on the encouraging results of Genzyme Corp.'s Phase II multiple sclerosis (MS) trial. It notes that the Genzyme, a subsidiary of Sanofi-Aventis Group, has showed that nearly two-third or 655 of patients treated with alemtuzumab remained free of clinically-active disease...

  • Adalimumab.  // Reactions Weekly;1/20/2007, Issue 1135, p5 

    The article presents a case study of multiple sclerosis in a 32-year-old woman treated with adalimumab for rheumatoid arthritis. Several months after receiving adalimumab, the patient developed acute loss of vision with pain in her left eye. Magnetic resonance imaging revealed multiple white...

  • Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra(r) (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article looks at the launch of a new website called Ampyra Journeys announced by Acorda Therapeutics Inc., a biotechnology company, focusing on the patients having walking problems associated with multiple sclerosis (MS). It says that Ampyra is an organic compound which is approved by the...

  • Cannabis pain trial success. Polak, Monika // GP: General Practitioner;10/6/2003, p28 

    A Great Britain study of a cannabis-based extract found it reduced pain in patients with multiple sclerosis. Researchers, from the Walton Centre for neurology and neurosurgery in Liverpool, say their trial is the first to show that a cannabis-based medicine can significantly reduce neuropathic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics